The first drug to substantially beat chemotherapy in decades
Pancreatic cancer has long occupied a particular place in the human experience of illness — a diagnosis that arrives late, moves fast, and leaves little room for hope. A new experimental drug called daraxonrasib, tested in a 500-patient trial and published in the New England Journal of Medicine, has nearly doubled median survival for patients with metastatic disease, reducing the risk of death by 60 percent compared to standard chemotherapy. The breakthrough works by targeting a genetic mutation long considered beyond the reach of medicine, and it arrives at a moment when thousands of Americans each year have had no better option than to measure their remaining time in months.
- Pancreatic cancer kills over 52,000 Americans annually, and until now its most common genetic driver — a KRAS mutation present in over 90% of cases — had resisted every attempt to develop a targeted treatment.
- Daraxonrasib extended median survival from 6.7 to 13.2 months in patients whose cancer had already stopped responding to prior therapy, a result that moved at least one leading oncologist to tears when she first saw the data.
- The drug works as a daily pill rather than an infusion, carries a lighter side effect burden than chemotherapy, and patients stayed on it longer — meaning the survival advantage may grow as follow-up continues.
- The FDA has already granted expedited review and launched an expanded access program, and oncologists report being flooded with patient requests; former Senator Ben Sasse, given three months to live in December, says the drug is 'crushing' his stage-four cancer six months later.
- Researchers are now planning trials for earlier-stage disease and potential combination with surgery, while other KRAS-targeting drugs and immune-based approaches are advancing through the pipeline.
For decades, pancreatic cancer has resisted the targeted breakthroughs that transformed treatment for other diseases. More than 52,000 Americans die from it each year, and those diagnosed with metastatic disease — cancer that has already spread — typically survive less than seven months on standard chemotherapy. That calculus may now be changing.
A new drug called daraxonrasib, tested in a randomized trial of 500 patients and published in the New England Journal of Medicine, extended median survival to 13.2 months — nearly double the comparison group — while reducing the risk of death by 60 percent. The drug targets mutations in the KRAS gene, present in over 90 percent of pancreatic cancers and long considered "undruggable" because the protein it produces seemed impossible to bind. Revolution Medicines solved this by developing what researchers call a molecular glue, allowing the drug to attach to multiple variants of the mutated protein. It is taken as a daily pill.
The emotional weight of the findings was visible in the scientific community's response. Dr. Rachna Shroff of the University of Arizona said she cried when she first saw the data — struck not only by the survival extension but by the durability of benefit and the quality of life patients reported as their tumors shrank. Side effects, including rashes and mouth sores in some patients, were meaningfully lighter than those of standard chemotherapy, and many patients were still taking the drug when the analysis concluded.
The FDA has granted expedited review and launched an expanded access program, and oncologists are already fielding waves of patient requests. Former Senator Ben Sasse, diagnosed with stage-four pancreatic cancer in December and initially given three months to live, began taking daraxonrasib and reported six months later that the drug is producing significant tumor shrinkage. Researchers are now planning to test the drug earlier in the disease course and to explore whether tumor reduction might open the door to surgery — currently available to only a small fraction of patients. For a disease that has long defeated experimental therapies, the landscape is beginning, carefully, to shift.
For decades, pancreatic cancer has resisted the kind of targeted drug breakthroughs that transformed treatment for other malignancies. The disease kills more than 52,000 Americans each year, and those diagnosed with the metastatic form—cancer that has spread beyond the pancreas—face a median survival of less than seven months on standard chemotherapy. This grim calculus may be shifting. A new experimental medication called daraxonrasib, tested in a randomized trial of 500 patients, extended median survival to 13.2 months, nearly doubling the time patients lived compared to those receiving conventional treatment. The drug reduced the risk of death by 60 percent.
The breakthrough targets a mutation in the KRAS gene family, found in more than 90 percent of pancreatic cancers. For years, this mutation was considered untreatable—the protein it produced seemed impossible for drugs to bind to, earning it the label "undruggable." Revolution Medicines developed daraxonrasib using what researchers describe as a molecular glue, a mechanism that allows the drug to attach to multiple variants of the mutated protein. The medication comes as a daily pill, a significant practical advantage over chemotherapy regimens. The study, published Sunday in the New England Journal of Medicine and presented at the American Society for Clinical Oncology meeting in Chicago, enrolled patients whose metastatic cancer had already stopped responding to prior treatment.
Dr. Zev Wainberg of UCLA, who led the research, described the results with measured language: "While not curing the cancer, it is a very large step forward." Yet the emotional weight of the finding was evident in the response from other oncologists. Dr. Rachna Shroff of the University of Arizona Cancer Center, who was not involved in the study, said she cried when she first saw the data. What struck her was not just the survival extension but the durability of benefit—patients remained on daraxonrasib longer than comparison patients stayed on chemotherapy, and they reported less pain and better quality of life as their tumors shrank. Many were still taking the drug when the analysis was completed, suggesting the survival advantage may widen as follow-up continues.
The side effect profile favored daraxonrasib as well. While severe rashes and mouth sores occurred in some patients, the overall burden of toxicity was lighter than with standard chemotherapy. This matters not in abstract terms but in the daily experience of people already facing a terminal diagnosis. The ability to take a pill at home rather than endure repeated infusions, combined with fewer debilitating side effects, translates to months of better functioning for patients and their families.
Dr. Brian Wolpin of Dana-Farber Cancer Institute, who presented the findings, called for daraxonrasib to become "a new standard of care" for previously treated metastatic pancreatic cancer. The FDA has already signaled its support, granting expedited review status and launching an expanded access program in May that allows eligible patients to receive the drug before formal approval. Oncologists are now being flooded with requests from patients seeking access. Former U.S. Senator Ben Sasse, diagnosed with stage-four pancreatic cancer in December and initially given three months to live, began taking daraxonrasib and reported in a statement to CBS News that six months later he remains alive and experiencing significant tumor shrinkage. "This is an incredible drug that's crushing my cancer in ways that were unimaginable just a few months ago," he said.
Researchers are already planning the next phase of investigation. Wainberg said the team will examine whether daraxonrasib works better against certain KRAS subtypes, potentially allowing for even more precise patient selection. Wolpin indicated interest in testing the drug earlier in the disease course, before cancer spreads, and exploring whether tumor shrinkage might allow more patients to become candidates for surgery—a curative option currently available to only a small fraction of pancreatic cancer patients. Other drugs targeting specific KRAS mutations are in development, and immunotherapy approaches, including vaccines designed to teach the immune system to recognize mutated proteins after surgery, are in earlier testing phases. For a disease that has long been a graveyard for experimental therapies, the landscape is beginning to shift.
Citas Notables
While not curing the cancer, it is a very large step forward— Dr. Zev Wainberg, UCLA
This is an incredible drug that's crushing my cancer in ways that were unimaginable just a few months ago— Former U.S. Senator Ben Sasse
La Conversación del Hearth Otra perspectiva de la historia
Why does this drug work when others targeting KRAS have failed for so long?
The mutation was considered untouchable—the protein's structure made it nearly impossible for drugs to stick to it. This one uses a molecular glue mechanism that can bind to multiple variants of the mutated protein at once. It's not that researchers didn't try before; the biology itself was the barrier.
The survival extension from 6.7 to 13.2 months—that's significant, but it's still not years. Why is this being called a breakthrough?
Because for pancreatic cancer, it's the first drug to substantially beat chemotherapy. For sixteen years, oncologists had nothing better to offer than the same drugs from decades past. An extra six months, when you're facing metastatic disease, is not a small thing. And patients stayed on it longer, with less pain. That changes how people actually live their final months.
What about the side effects—rashes and mouth sores sound serious.
They can be, but they're manageable compared to chemotherapy's toxicity. The key is that fewer patients had to stop taking it because of side effects. More people could stay on the drug long enough to benefit from it.
The FDA is already offering expanded access. How does that work for patients?
It's a program that lets people with certain criteria get the drug before it's formally approved, if they meet the requirements. Oncologists are being flooded with requests. It's a recognition that waiting for standard approval timelines isn't acceptable when people are dying.
What happens next? Is this the end of the story?
No. Researchers want to test it earlier in the disease, before cancer spreads. They're also looking at whether it could shrink tumors enough to make surgery possible for more patients. And there are dozens of other experimental drugs in the pipeline targeting the same mutation. This is the first domino falling.
So this changes pancreatic cancer treatment fundamentally?
It's the first real shift in decades. For a disease with a 13 percent five-year survival rate, that matters enormously.